Century Therapeutics, Inc.
IPSC
$0.51
-$0.02-3.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4,121.12% | 5,489.03% | 8,286.79% | 194.85% | 7.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4,121.12% | 5,489.03% | 8,286.79% | 194.85% | 7.92% |
| Cost of Revenue | 5.17% | 14.96% | 21.01% | 15.68% | 4.34% |
| Gross Profit | 108.20% | 104.36% | 105.00% | -11.25% | -4.24% |
| SG&A Expenses | -5.39% | -2.74% | -1.07% | -0.56% | -1.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.49% | 10.26% | 14.95% | 11.25% | 2.91% |
| Operating Income | 81.62% | 76.94% | 76.14% | -7.98% | -2.82% |
| Income Before Tax | 81.11% | 83.66% | 84.82% | 7.43% | -3.62% |
| Income Tax Expenses | 307.96% | 796.06% | 165.58% | -4.78% | -130.70% |
| Earnings from Continuing Operations | 79.62% | 82.28% | 83.56% | 7.39% | -0.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 79.62% | 82.28% | 83.56% | 7.39% | -0.73% |
| EBIT | 81.62% | 76.94% | 76.14% | -7.98% | -2.82% |
| EBITDA | 90.42% | 85.57% | 85.25% | -8.67% | -2.07% |
| EPS Basic | 83.42% | 86.35% | 87.34% | 29.57% | 15.22% |
| Normalized Basic EPS | 89.48% | 87.31% | 87.82% | 18.13% | 17.59% |
| EPS Diluted | 83.19% | 86.15% | 87.28% | 29.51% | 15.16% |
| Normalized Diluted EPS | 89.43% | 87.27% | 87.78% | 18.13% | 17.59% |
| Average Basic Shares Outstanding | 19.04% | 29.77% | 40.35% | 32.53% | 22.70% |
| Average Diluted Shares Outstanding | 19.07% | 29.80% | 40.38% | 32.53% | 22.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |